ORIGINAL PAPER
Potential biomarkers in Behçet’s disease: monocyte, neutrophil, platelet, and C-reactive protein to albumin ratios
More details
Hide details
1
Department of Internal Medicine, Rheumatology Division, Ataturk University School of Medicine, Erzurum, Turkey
2
Department of Physical Medicine and Rehabilitation, Ataturk University School of Medicine, Erzurum, Turkey
3
Department of Physical Medicine and Rehabilitation, Rheumatology Division, Ataturk University School of Medicine, Erzurum, Turkey
Submission date: 2024-06-04
Final revision date: 2024-07-30
Acceptance date: 2024-08-16
Online publication date: 2024-11-06
Corresponding author
Meltem Alkan Melikoglu
Department of Physical Medicine and Rehabilitation, Rheumatology Division, Ataturk University School
of Medicine, 25100, Erzurum, Turkey
Reumatologia 2024;62(5):308-313
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The objective of this cross-sectional study was to evaluate the monocyte to albumin ratio (MAR), neutrophil to albumin ratio (NAR), platelet to albumin ratio (PAR), and C-reactive protein to albumin ratio (CAR) as potential biomarkers for disease activity in patients with Behçet’s disease (BD).
Material and methods:
Both BD cases and healthy controls were enrolled in this study. Demographic characteristics, disease duration, and current medications were recorded for all participants. The BD Current Activity Form (BDCAF) was utilized to assess the activity of BD. Additionally, erythrocyte sedimentation rate, CRP, and serum albumin levels were measured. The MAR, NAR, PAR, and CAR were compared between the two groups. Correlation analysis and receiver operating characteristic curves (ROC) were employed to establish cut-off points for these biomarkers.
Results:
In the study, both BD cases and 45 controls were included, totaling 90 participants. Significant differences were observed in the mean ±SD values of ESR, MAR, PAR, CAR, and albumin between the BD cases and controls (p = 0.008, p = 0.009, p = 0.029, p = 0.034, p = 0.006, respectively). However, despite these differences, no significant correlation was detected between BDCAF and the parameters under investigation. The cutoff point was determined as 150.59 (sensitivity 46.67%, specificity 82.22%, p = 0.008, AUC = 0.655) for MAR; as 62,013.73 (sensitivity 60.00%, specificity 66.67%, p = 0.03, AUC = 0.629) for PAR; and as 1.16 (sensitivity 35.56%, specificity of 95.567%, p = 0.03, AUC = 0.629) for CAR. The results were not able to define any cut-off points for active-inactive BD.
Conclusions:
Significantly higher levels of MAR, PAR, and CAR were observed in patients with BD than controls. Monocyte to albumin ratio, PAR, and CAR were notably elevated in patients with active BD. This finding suggests that these parameters possess discriminative ability and could potentially serve as biomarkers to aid in the clinical evaluation of BD.
REFERENCES (25)
1.
Açarı C, İşgüder R, Torun R, et al. Pediatric Behçet’s disease: experience of a single tertiary center. Arch Rheumatol 2022; 38: 282–290, DOI: 10.46497/ArchRheumatol.2023.9651.
2.
Karaca D, Dıraçoğlu A, Önder F. Can optical coherence tomography angiography be a first line ophthalmological evaluation in patients with Behçet’s disease? Arch Rheumatol 2022; 38: 200–208, DOI: 10.46497/ArchRheumatol.2023.9494.
3.
Enginar AU. C-reactive protein to albumin ratio in Behçet’s disease. Eur Res J 2022; 8: 777–782, DOI: 10.18621/eurj.1090380.
4.
Saito N, Shirai Y, Horiuchi T, et al. Preoperative platelet to albumin ratio predicts outcome of patients with cholangiocarcinoma. Anticancer Res 2018; 38: 987–992, DOI: 10.21873/anticanres.12313.
5.
Shirai Y, Shiba H, Haruki K, et al. Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Res 2017; 37: 787–793, DOI: 10.21873/anticanres.11378.
6.
Chen CH, Chen HA, Liao HT, et al. The clinical usefulness of ESR, CRP, and disease duration in ankylosing spondylitis: the product of these acute-phase reactants and disease duration is associated with patient’s poor physical mobility. Rheumatol Int 2015; 35: 1263–1267, DOI: 10.1007/s00296-015-3214-4.
7.
Tan J, Song G, Wang S, et al. Platelet-to-albumin ratio: a novel IgA nephropathy prognosis predictor. Front Immunol 2022; 13: 842362, DOI: 10.3389/fimmu.2022.842362.
8.
Chen S, Ying H, Du J, et al. The association between albumin-dNLR score and disease activity in patients with rheumatoid arthritis. J Clin Lab Anal 2019; 33: e22695, DOI: 10.1002/jcla.22695.
9.
Jung JY, Lee E, Suh CH, Kim HA. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. J Clin Lab Anal 2019; 33: e23000, DOI: 10.1002/jcla.23000.
10.
Zhong Z, Huang Y, Liu Y, et al. Correlation between C-reactive protein to albumin ratio and disease activity in patients with axial spondyloarthritis. Dis Markers 2021; 2021: 6642486, DOI: 10.1155/2021/6642486.
11.
Moon JS, Ahn SS, Park YB, et al. C-Reactive protein to serum albumin ratio is an independent predictor of all-cause mortality in patients with ANCA-associated vasculitis. Yonsei Med J 2018; 59: 865–871, DOI: 10.3349/ymj.2018.59.7.865.
12.
Liu X, Wang L, Zhou K, et al. Predictive value of C-reactive protein to albumin ratio as a biomarker for initial and repeated intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients: a prospective cohort study. Pediatr Rheumatol Online J 2021; 19: 24, DOİ: 10.1186/s12969-021-00517-1.
13.
International Study Group for Behcet’s disease. Criteria for diagnosis of Behcet’s disease. Lancet 1990; 335: 1078–1080.
14.
Kim M, Park YG, Park YH. C-reactive protein/albumin ratio as an indicator of disease activity in Behçet’s disease and human leukocyte antigen-B27-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2021; 259: 1985–1992, DOI: 10.1007/s00417-021-05207-y.
15.
Bhakta BB, Brennan P, James TE, et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728–733, DOI: 10.1093/rheumatology/38.8.728.
16.
Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet’s disease activity index. Rheumatology (Oxford) 2004; 43: 73–78, DOI: 10.1093/rheumatology/keg453.
17.
Hamuryudan V, Fresko I, Direskeneli H, et al. Evaluation of the Turkish translation of a disease activity form for Behçet’s syndrome. Rheumatology (Oxford) 1999; 38: 734–736, DOI: 10.1093/rheumatology/38.8.734.
18.
Neves FD, Caldas CAM, Medeiros DMD, et al. Cross-cultural adaptation of simplified version (s) of Behçet’s Disease Current Activity Form (BDCAF) and comparison between two different instruments with Brazilian versions for evaluating Behçet’s Disease Activity: BR-BDCAF and BR-BDCAF(s). Rev Bras Reumatol 2009; 49: 20–31, DOI: 10.1007/s10067-006-0484-y.
19.
Hatemi G, Esatoglu SN, Yazici Y. Biomarkers in vasculitis. Curr Opin Rheumatol. 2018; 30: 30–35, DOI: 10.1097/BOR.0000000000000447.
20.
Ataş N, Babaoğlu H, Demirel E, et al. Use of prognostic nutritional index in the evaluation of disease activity in patients with Behçet’s disease. Eur J Rheumatol 2020; 7: 99–104, DOI: 10.5152/eurjrheum.2020.20010.
21.
Melikoglu M, Topkarci Z. Is there a relation between clinical disease activity and acute phase response in Behcet’s disease? Int J Dermatol 2014: 53: 250–254, DOI: 10.1111/ijd.12224.
22.
Liu M, Huang Y, Huang Z, et al. New inflammatory marker associated with disease activity in patients with rheumatoid arthritis: platelet to albumin ratio. Ann Rheum Dis 2022; 9 (1 Suppl): 1398–1398.
23.
Huang Y, Deng W, Pan X, et al. The relationship between platelet to albumin ratio and disease activity in axial spondyloarthritis patients. Mod Rheumatol 2022; 32: 974–979, DOI: 10.1093/mr/roab060.
24.
Atas DB, Sahin GK, Şengül Ş, et al. C-reactive protein to albumin ratio is associated with disease activity in anti-neutrophil cytoplasmic antibody associated vasculitis. Mediterr J Rheumatol 2023; 34: 71–77, DOI: 10.31138/mjr.34.1.71.
25.
Tanacan E, Dincer D, Erdogan FG, Gurler A. A cutoff value for the Systemic Immune-Inflammation Index in determining activity of Behçet disease. Clin Exp Dermatol 2021; 46: 286–291, DOI: 10.1111/ced.14432.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.